- Email: [email protected]
Information for category 1 CME Credit
T HE J OURNAL OF
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted. Date of Original Release: October 2007. Credit may be obtained for these courses until September 30, 2009. Copyright Statement: Copyright Ó 2007-2009. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for a maximum of 1 AMA PRA Category 1 CreditÔ. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME article
CME article
‘‘Novel insights from adaptor protein 3 complex deficiency’’ (page 735)
‘‘Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: Foxp3 mutations and lack of regulatory T cells’’ (page 744)
List of Design Committee Members: Authors: Raffaele Badolato, MD, PhD, and Silvia Parolini, PhD Activity Objectives 1. To describe the clinical features of Hermansky-Pudlak syndrome type 2 (HPS2), which is caused by adaptor protein 3 (AP-3) deficiency. 2. To define the immune role of the AP-3 complex. 3. To define the physiopathology of the AP-3 complex. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Raffaele Badolato and Silvia Parolini have no significant relationships to disclose.
44A October 2007
List of Design Committee Members: Authors: Troy R. Torgerson, MD, PhD, and Hans D. Ochs, MD Activity Objectives 1. To recognize the main clinical manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and differentiate between it and other primary immune deficiency disorders. 2. To recognize laboratory parameters associated with IPEX. 3. To understand the molecular basis of forkhead box protein 3 (FOXP3) mutations in IPEX and the function of regulatory T cells (Tregs). 4. To recognize the current treatment modalities for IPEX. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Troy R. Torgerson and Hans D. Ochs have no significant relationships to disclose.
J ALLERGY CLIN IMMUNOL
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted. Date of Original Release: October 2007. Credit may be obtained for these courses until September 30, 2009. Copyright Statement: Copyright Ó 2007-2009. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for a maximum of 1 AMA PRA Category 1 CreditÔ. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME article
CME article
‘‘Novel insights from adaptor protein 3 complex deficiency’’ (page 735)
‘‘Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: Foxp3 mutations and lack of regulatory T cells’’ (page 744)
List of Design Committee Members: Authors: Raffaele Badolato, MD, PhD, and Silvia Parolini, PhD Activity Objectives 1. To describe the clinical features of Hermansky-Pudlak syndrome type 2 (HPS2), which is caused by adaptor protein 3 (AP-3) deficiency. 2. To define the immune role of the AP-3 complex. 3. To define the physiopathology of the AP-3 complex. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Raffaele Badolato and Silvia Parolini have no significant relationships to disclose.
44A October 2007
List of Design Committee Members: Authors: Troy R. Torgerson, MD, PhD, and Hans D. Ochs, MD Activity Objectives 1. To recognize the main clinical manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and differentiate between it and other primary immune deficiency disorders. 2. To recognize laboratory parameters associated with IPEX. 3. To understand the molecular basis of forkhead box protein 3 (FOXP3) mutations in IPEX and the function of regulatory T cells (Tregs). 4. To recognize the current treatment modalities for IPEX. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Troy R. Torgerson and Hans D. Ochs have no significant relationships to disclose.
J ALLERGY CLIN IMMUNOL